Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 20, Issue 3, 2010, Pages 711-722

  Carlsson, Cynthia M ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

Alzheimer's disease; biological markers; cognition; diabetes mellitus; dyslipidemia; prevention

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN; ANGIOTENSIN CONVERTING ENZYME 2; APOLIPOPROTEIN E; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULINASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SOMATOMEDIN C RECEPTOR; STATIN; TRIACYLGLYCEROL;

AGING; ALZHEIMER DISEASE; BRAIN BLOOD FLOW; BRAIN INFARCTION; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LEARNING; MEMORY; MENTAL CAPACITY; METABOLIC SYNDROME X; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NEUROBIOLOGY; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENILE PLAQUE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77954546616     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100012     Document Type: Review

References (108)

1. Mucke L (2009) Neuroscience: Alzheimer's disease. Nature 461, 895-897.
2. Prince M, Jackson J, World Alzheimer Report, http://www. alz.co.uk/research/files/World%20Alzheimer%20Report.pdf, Accessed December 31, 2009.
3. (2009) Estimated county-level prevalence of diabetes and obesity - United States, 2007. MMWR Morb Mortal Wkly Rep 58, 1259-1263.
4. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H (2002) Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 137, 149-155.
5. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I (2003) An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 163, 1524-1528.
6. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53, 1937-1942.
7. Iadecola C (2004) Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 5, 347-360.
8. de la Torre JC (2002) Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33, 1152-1162.
9. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5, 64-74. (Pubitemid 41790697)
10. Kopf D, Frolich L (2009) Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. J Alzheimers Dis 16, 677-685.
11. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Nomiyama K, Kawano H, Ueda K, et al. (1995) Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology 45, 1161-1168.
12. Peila R, Rodriguez BL, Launer LJ (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262.
13. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61, 661-666.
14. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145, 301-308. (Pubitemid 27082028)
15. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R (2005) Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65, 545-551.
16. Brayne C, Gill C, Huppert FA,BarkleyC, GehlhaarE, Girling DM, O'Connor DW, Paykel ES (1998) Vascular risks and incident dementia: results from a cohort study of the very old. Dement Geriatr Cogn Disord 9, 175-180.
17. Curb JD, Rodriguez BL, Abbott RD, Petrovitch H, Ross GW, Masaki KH, Foley D, Blanchette PL, Harris T, Chen R, White LR (1999) Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 52, 971-975.
18. Yamada M, Kasagi F, Sasaki H, Masunari N, MimoriY, Suzuki G (2003) Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc 51, 410-414.
19. Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA,Wolf PA, Seshadri S (2006) Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol 63, 1551-1555.
20. Hayden KM, Zandi PP, Lyketsos CG, Khachaturian AS, Bastian LA, Charoonruk G, Tschanz JT, Norton MC, Pieper CF, Munger RG, Breitner JC, Welsh-Bohmer KA (2006) Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord 20, 93-100.
21. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R (2001) Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154, 635-641.
22. MacKnight C, Rockwood K,Awalt E, McDowell I (2002) Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 14, 77-83. (Pubitemid 36152948)
23. Tyas SL, Manfreda J, Strain LA, Montgomery PR (2001) Risk factors for Alzheimer's disease: a population-based, longitudinal study in Manitoba, Canada. Int J Epidemiol 30, 590-597.
24. Xu WL, Qiu CX,Wahlin A,Winblad B, Fratiglioni L (2004) Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 63, 1181-1186.
25. Toro P, Schonknecht P, Schroder J (2009) Type II diabetes in mild cognitive impairment and Alzheimer's disease: results from a prospective population-based study in Germany. J Alzheimers Dis 16, 687-691.
26. Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L (2009) Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. Diabetologia 52, 1031-1039.
27. XuW, Qiu C, Gatz M, Pedersen NL, Johansson B, Fratiglioni L (2009) Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes 58, 71-77.
28. Kivipelto M, Ngandu T, Fratiglioni L,Viitanen M, Kareholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A (2005) Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62, 1556-1560. (Pubitemid 41434560)
29. Launer LJ, RossGW, Petrovitch H, Masaki K, FoleyD, White LR, Havlik RJ (2000) Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 21, 49-55.
30. Whitmer RA, Sidney S, Selby J, Johnston SC,Yaffe K (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64, 277-281.
31. Velayudhan L, Poppe M, Archer N, Proitsi P, Brown RG, Lovestone S Risk of developing dementia in people with diabetes and mild cognitive impairment. Br J Psychiatry 196, 36-40.
32. Xu W, Qiu C, Winblad B, Fratiglioni L (2007) The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 56, 211-216.
33. Luchsinger JA, Tang MX, Shea S, Mayeux R (2004) Hyperinsulinemia and risk of Alzheimer disease. Neurology 63, 1187-1192.
34. Peila R, Rodriguez BL, White LR, Launer LJ (2004) Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology 63, 228-233.
35. Ronnemaa E, Zethelius B, Sundelof J, Sundstrom J, Degerman-Gunnarsson M, Berne C, Lannfelt L, Kilander L (2008) Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 71, 1065-1071.
36. Sanz C, Andrieu S, Sinclair A, Hanaire H, Vellas B (2009) Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology 73, 1359-1366.
37. Carlsson CM, Gleason CE, Hess TM, Moreland KA, Blazel HM, Koscik RL, Schreiber NT, Johnson SC, Atwood CS, Puglielli L, Hermann BP, McBride PE, Stein JH, Sager MA, Asthana S (2008) Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. J Alzheimers Dis 13, 187-197.
38. Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, Yasar S, Atkinson H, Robbins M, Psaty B, Goff DC, Jr. (2009) Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med 169, 1195-1202.
39. Awad N, Gagnon M, Messier C (2004) The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol 26, 1044-1080.
40. Strachan MW, Deary IJ, Ewing FM, Frier BM (1997) Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 20, 438-445.
41. Allen KV, Frier BM, Strachan MW (2004) The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 490, 169-175.
42. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB (2004) The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292, 2237-2242.
43. Yaffe K, Weston AL, Blackwell T, Krueger KA (2009) The metabolic syndrome and development of cognitive impairment among older women. Arch Neurol 66, 324-328.
44. Muller M, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA (2007) Metabolic syndrome and dementia risk in a multiethnic elderly cohort. Dement Geriatr Cogn Disord 24, 185-192.
45. Berry C, Tardif JC, Bourassa MG (2007) Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. J Am Coll Cardiol 49, 631-642. (Pubitemid 46205041)
46. Hall K, Murrell J, Ogunniyi A, Deeg M, Baiyewu O, Gao S, Gureje O, Dickens J, Evans R, Smith-Gamble V, Unverzagt FW, Shen J, Hendrie H (2006) Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology 66, 223-227.
47. Watson GS, Craft S (2004) Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 490, 97-113.
48. Carlsson CM, Nondahl DM, Klein BE, McBride PE, Sager MA, Schubert CR, Klein R, Cruickshanks KJ (2009) Increased atherogenic lipoproteins are associated with cognitive impairment: effects of statins and subclinical atherosclerosis. Alzheimer Dis Assoc Disord 23, 11-17.
49. de la Torre JC (2004) Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3, 184-190.
50. Iadecola C, Zhang F, Niwa K, Eckman C, Turner SK, Fischer E, Younkin S, Borchelt DR, Hsiao KK, Carlson GA (1999) SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci 2, 157-161.
51. Price JM, Chi X, Hellermann G, Sutton ET (2001) Physiological levels of beta-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production. Neurol Res 23, 506-512.
52. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M (1996) beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380, 168-171.
53. Niwa K, Carlson GA, Iadecola C (2000) Exogenous A beta1- 40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab 20, 1659-1668.
54. Sparks DL, Scheff SW, Hunsaker JC, 3rd, Liu H, Landers T, Gross DR (1994) Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126, 88-94.
55. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7, 321-331.
56. Liu Y, Liu H, Yang J, Liu X, Lu S, Wen T, Xie L, Wang G (2008) Increased amyloid beta-peptide (1-40) level in brain of streptozotocin-induced diabetic rats. Neuroscience 153, 796-802.
57. Drexler H, Zeiher AM (1991) Endothelial function in human coronary arteries in vivo. Focus on hypercholesterolemia. Hypertension 18, II90-99.
58. Xu J, Zou MH (2009) Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation 120, 1266-1286.
59. Paris D, Town T, Humphrey J, Yokota K, Mullan M (2000) Cholesterol modulates vascular reactivity to endothelin-1 by stimulating a pro-inflammatory pathway. Biochem Biophys Res Commun 274, 553-558.
60. Chen Y, Huang Y, Li X, Xu M, Bi Y, Zhang Y, Gu W, Ning G (2009) Association of arterial stiffness with HbA1c in 1,000 type 2 diabetic patients with or without hypertension. Endocrine 36, 262-267.
61. Jones A, Kulozik P, Ostertag A, Herzig S (2009) Common pathological processes and transcriptional pathways in Alzheimer's disease and type 2 diabetes. J Alzheimers Dis 16, 787-808.
62. de la Monte SM, Wands JR (2008) Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2, 1101-1113.
63. LiuY, Liu F, Grundke-Iqbal I, Iqbal K, GongCX(2009)Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J Neurochem 111, 242-249.
64. Gerozissis K (2008) Brain insulin, energy and glucose homeostasis; genes, environment and metabolic pathologies. Eur J Pharmacol 585, 38-49.
65. Craft S, Watson GS (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3, 169-178.
66. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273, 32730-32738.
67. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100, 4162-4167.
68. Watson GS, Peskind ER, Asthana S, Purganan K, Wait C, Chapman D, Schwartz MW, Plymate S, Craft S (2003) Insulin increases CSF Abeta42 levels in normal older adults. Neurology 60, 1899-1903.
69. Needham BE, Wlodek ME, Ciccotosto GD, Fam BC, Masters CL, Proietto J, Andrikopoulos S, Cappai R (2008) Identification of the Alzheimer's disease amyloid precursor protein (APP) and its homologue APLP2 as essential modulators of glucose and insulin homeostasis and growth. J Pathol 215, 155-163.
70. Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, Fujii N, Koike T, Wakayama I, Yanagihara R, Garruto R, Amano N, Makita Z (1998) Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol 153, 1149-1155.
71. Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T (2003) Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res 23, 129-134.
72. Valente T, Gella A, Fernandez-Busquets X, Unzeta M, Durany N Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis 37, 67-76.
73. Hauptmann S, Scherping I, Drose S, Brandt U, Schulz KL, Jendrach M, Leuner K, Eckert A, Muller WE (2009) Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 30, 1574-1586.
74. Lowell BB, Shulman GI (2005) Mitochondrial dysfunction and type 2 diabetes. Science 307, 384-387.
75. Barzilaym JI, Freedland ES (2003) Inflammation and its relationship to insulin resistance, type 2 diabetes mellitus, and endothelial dysfunction. Metab Syndr Relat Disord 1, 55-67.
76. Finch CE, Morgan TE (2007) Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: a position paper. Curr Alzheimer Res 4, 185-189.
77. Taguchi A (2009) Vascular factors in diabetes and Alzheimer's disease. J Alzheimers Dis 16, 859-864.
78. Bondy CA, Cheng CM (2004) Signaling by insulin-like growth factor 1 in brain. Eur J Pharmacol 490, 25-31.
79. Johnson PC, Brendel K, Meezan E (1982) Thickened cerebral cortical capillary basement membranes in diabetics. Arch Pathol Lab Med 106, 214-217.
80. Hossmann KA (1994) Viability thresholds and the penumbra of focal ischemia. Ann Neurol 36, 557-565.
81. Martin KC, Barad M, Kandel ER (2000) Local protein synthesis and its role in synapse-specific plasticity. Curr Opin Neurobiol 10, 587-592.
82. Sonnen JA, Larson EB, Brickell K, Crane PK, Woltjer R, Montine TJ, Craft S (2009) Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol 66, 315-322.
83. Novak V, Last D, Alsop DC, Abduljalil AM, Hu K, Lepicovsky L, Cavallerano J, Lipsitz LA (2006) Cerebral blood flow velocity and periventricular white matter hyperintensities in type 2 diabetes. Diabetes Care 29, 1529-1534.
84. Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC, Jagust WJ, Gorno-Tempini ML, Schuff N (2005) Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 234, 851-859.
85. Chertkow H, Black S (2007) Imaging biomarkers and their role in dementia clinical trials. Can J Neurol Sci 34(Suppl 1), S77-83.
86. Evans RM, Emsley CL, Gao S, Sahota A, Hall KS, Farlow MR, Hendrie H (2000) Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 54, 240-242.
87. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB (1995) Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45, 1092-1096.
88. Solomon A, Kareholt I, Ngandu T, Wolozin B, Macdonald SW, Winblad B, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M (2009) Serum total cholesterol, statins and cognition in non-demented elderly. Neurobiol Aging 30, 1006-1009.
89. Burgess BL, McIsaac SA, Naus KE, Chan JY, Tansley GH, Yang J, Miao F, Ross CJ, van Eck M, Hayden MR, van Nostrand W, St George-Hyslop P, Westaway D, Wellington CL (2006) Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma. Neurobiol Dis 24, 114-127.
90. Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, Stern Y (2009) Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 66, 343-348.
91. Raffaitin C, Gin H, Empana JP, Helmer C, Berr C, Tzourio C, Portet F, Dartigues JF, Alperovitch A, Barberger-Gateau P (2009) Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 32, 169-174.
92. Watanabe T,Koba S, Kawamura M, Itokawa M, Idei T, Nakagawa Y, Iguchi T, Katagiri T (2004) Small dense low-density lipoprotein and carotid atherosclerosis in relation to vascular dementia. Metabolism 53, 476-482.
93. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13, 950-958.
94. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6, 246-254.
95. Roses AD(2008) Commentary on "a roadmap for the prevention of dementia: the inaugural Leon Thal Symposium." An impending prevention clinical trial for Alzheimer's disease: roadmaps and realities. Alzheimers Dement 4, 164-166.
96. Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease, http://clinicaltrials.gov/ct2/show/ NCT00428090, Accessed January 3, 2010.
97. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T (2009) Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging, in press.
98. Pioglitazone in Alzheimer Disease. http://www.clinicaltrials. gov/ct2/show/NCT00982202?term=diabetes+AND+Alzhei mer%27s+disease&rank=7, Accessed January 3, 2010.
99. Metformin in Amnestic Mild Cognitive Impairment (MCI), http://www.clinicaltrials.gov/ct2/show/NCT00620191?term = diabetes+AND+Alzheimer%27s+disease&rank=3, Accessed January 3, 2010.
100. Reger MA,Watson GS, Green PS,Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70, 440-448.
101. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344, 1343-1350. (Pubitemid 32378388)
102. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM,Walker EA, Nathan DM (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346, 393-403.
103. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368, 1096-1105.
104. Luchsinger JA, Gustafson DR (2009) Adiposity, type 2 diabetes, and Alzheimer's disease. J Alzheimers Dis 16, 693-704.
105. Williamson JD, Miller ME, Bryan RN, Lazar RM, Coker LH, Johnson J, Cukierman T, Horowitz KR, Murray A, Launer LJ (2007) The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. Am J Cardiol 99, 112i-122i.
106. Watson GS, Bernhardt T, Reger MA, Cholerton BA, Baker LD, Peskind ER, Asthana S, Plymate SR, Frolich L, Craft S (2006) Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease. Neurobiol Aging 27, 38-41.
107. Ferris SH, Aisen PS, Cummings J, Galasko D, Salmon DP, Schneider L, Sano M, Whitehouse PJ, Edland S, Thal LJ (2006) ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord 20, S109-123.
108. Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M (2007) A neuropsychological test battery for use in Alzheimer disease clinical trials. ArchNeurol 64, 1323-1329.